Cargando…

A Novel Immunotype-based Risk Stratification Model Predicts Postoperative Prognosis and Adjuvant TACE Benefit in Chinese Patients with Hepatocellular Carcinoma

Background and Aims: The tumor microenvironment can be divided into inflamed, immune-excluded and immune-desert phenotypes according to CD8(+) T cell categories with differential programmed cell death protein 1 (PD-L1) expression. The study aims to construct a novel immunotype-based risk stratificat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Tian-En, Zhang, Ze, Wang, Yi, Xu, Da, Dong, Jian, Zhu, Ying, Wang, Zheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2021
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8040877/ https://www.ncbi.nlm.nih.gov/pubmed/33854587 http://dx.doi.org/10.7150/jca.54408

Ejemplares similares

Cezanne predicts progression and adjuvant TACE response in hepatocellular carcinoma
por: Wang, Jia-hong, et al.
Publicado: (2017)

Serum alanine aminotransferase to hemoglobin ratio and radiological features predict the prognosis of postoperative adjuvant TACE in patients with hepatocellular carcinoma
por: Xia, Zicong, et al.
Publicado: (2022)

RMP predicts survival and adjuvant TACE response in hepatocellular carcinoma
por: Zhang, Jian, et al.
Publicado: (2014)

Nomogram for individualized prediction of recurrence after postoperative adjuvant TACE for hepatitis B virus-related hepatocellular carcinoma
por: Jiang, Jiang, et al.
Publicado: (2017)

Identification and Validation of Tumor Stromal Immunotype in Patients With Hepatocellular Carcinoma
por: Li, Wei, et al.
Publicado: (2019)

Postoperative adjuvant TACE-associated nomogram for predicting the prognosis of resectable Hepatocellular Carcinoma with portal vein Tumor Thrombus after Liver Resection
por: Liu, Fuchen, et al.
Publicado: (2020)

Advances in immunotyping of colorectal cancer
por: Wu, Yinhang, et al.
Publicado: (2023)

Evaluation of the Benefits of TACE Combined with Sorafenib for Hepatocellular Carcinoma Based on Untreatable TACE (unTACEable) Progression
por: Zou, Xinhua, et al.
Publicado: (2021)

Identification of TP53 mutation associated-immunotype and prediction of survival in patients with hepatocellular carcinoma
por: Shi, Muqi, et al.
Publicado: (2020)

TACE-Sorafenib With Thermal Ablation Has Survival Benefits in Patients With Huge Unresectable Hepatocellular Carcinoma
por: Wu, Ying, et al.
Publicado: (2020)

The Prognosis of Hepatocellular Carcinoma Treated with Sorafenib in Combination with TACE
por: Kimura, Yusuke, et al.
Publicado: (2020)

Surgical Margin Affects the Long-Term Prognosis of Patients With Hepatocellular Carcinoma Undergoing Radical Hepatectomy Followed by Adjuvant TACE
por: Bai, Shilei, et al.
Publicado: (2023)

Postoperative adjuvant TACE for patients of hepatocellular carcinoma in AJCC stage I: friend or foe? a propensity score analysis
por: Tong, Yifan, et al.
Publicado: (2017)

COCH predicts survival and adjuvant TACE response in patients with HCC
por: Wang, Chen, et al.
Publicado: (2021)

Prognostic nomogram for post-surgical treatment with adjuvant TACE in hepatitis B virus-related hepatocellular carcinoma
por: Hu, Hao, et al.
Publicado: (2016)

TACE versus TACE + entecavir versus TACE + tenofovir in the treatment of HBV associated hepatocellular carcinoma
por: Lu, Haohao, et al.
Publicado: (2023)

Transarterial Chemoembolization of Child-A hepatocellular carcinoma: Drug-eluting bead TACE (DEB TACE) vs. TACE with Cisplatin/Lipiodol (cTACE)
por: Wiggermann, Philipp, et al.
Publicado: (2011)

Efficacy and safety of TACE in combination with sorafenib for the treatment of TACE-refractory advanced hepatocellular carcinoma in Chinese patients: a retrospective study
por: Wu, Jianbing, et al.
Publicado: (2017)

Immune Gene Signatures and Immunotypes in Immune Microenvironment Are Associated With Glioma Prognose
por: Wang, Xiang-Xu, et al.
Publicado: (2022)

Efficacy of drug-eluting bead transarterial chemoembolization (DEB-TACE) combined with radiofrequency ablation versus DEB-TACE alone in Chinese hepatocellular carcinoma patients
por: Zhu, Dedong, et al.
Publicado: (2019)

Deep Learning Reveals Key Immunosuppression Genes and Distinct Immunotypes in Periodontitis
por: Ning, Wanchen, et al.
Publicado: (2021)

Transarterial Chemoembolization (TACE) Combined with Sorafenib versus TACE Alone for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Study
por: Ren, Baosheng, et al.
Publicado: (2019)

Quantitative washout in patients with hepatocellular carcinoma undergoing TACE: an imaging biomarker for predicting prognosis?
por: Müller, Lukas, et al.
Publicado: (2022)

Tumor SOCS3 methylation status predicts the treatment response to TACE and prognosis in HCC patients
por: Jiang, Bei-Ge, et al.
Publicado: (2017)

The role of scheduled second TACE in early-stage hepatocellular carcinoma with complete response to initial TACE
por: Kim, Jung Hee, et al.
Publicado: (2017)

TACE and conformal radiotherapy vs. TACE alone for hepatocellular carcinoma: A randomised controlled trial
por: Féray, Cyrille, et al.
Publicado: (2023)

Optimal interventional treatment for liver cancer: HAIC, TACE or iTACE?
por: Ge, Naijian, et al.
Publicado: (2023)

Natural killer cell immunotypes related to COVID-19 disease severity
por: Maucourant, Christopher, et al.
Publicado: (2020)

High-dimensional immunotyping of tumors grown in obese and non-obese mice
por: Wogsland, Cara E., et al.
Publicado: (2021)

Comparison of Efficacy and Safety of TACE Combined with Microwave Ablation and TACE Combined with Cryoablation in the Treatment of Large Hepatocellular Carcinoma
por: Wang, Yujia, et al.
Publicado: (2022)

Aspartate aminotransferase-to-platelet ratio index predicts prognosis of hepatocellular carcinoma after postoperative adjuvant transarterial chemoembolization
por: Zhu, Gui-Qi, et al.
Publicado: (2018)

Diffuse Recurrence of Hepatocellular Carcinoma After Liver Resection: Transarterial Chemoembolization (TACE) Combined With Sorafenib Versus TACE Monotherapy
por: Yao, Wang, et al.
Publicado: (2020)

Development of TACE Refractoriness Scores in Hepatocellular Carcinoma
por: Chen, Li, et al.
Publicado: (2021)

Efficacy of adjuvant TACE on the prognosis of patients with HCC after hepatectomy: a multicenter propensity score matching from China
por: Wu, Zhao, et al.
Publicado: (2023)

Genetically predicted vitamin C levels significantly affect patient survival and immunotypes in multiple cancer types
por: Yuan, Jing, et al.
Publicado: (2023)

Impact of serum C-reactive protein level on the prognosis of patients with hepatocellular carcinoma undergoing TACE
por: Jun, Chung Hwan, et al.
Publicado: (2013)

Outcome of TACE treatment in HIV infected patients with hepatocellular carcinoma
por: Kong, Lingxiang, et al.
Publicado: (2021)

The incidence and outcome of major complication following conventional TAE/TACE for hepatocellular carcinoma
por: Tu, Jianfei, et al.
Publicado: (2016)

Development of ensemble learning models for prognosis of hepatocellular carcinoma patients underwent postoperative adjuvant transarterial chemoembolization
por: Liang, Yuxin, et al.
Publicado: (2023)

Prognostic factors and predictors of postoperative adjuvant transcatheter arterial chemoembolization benefit in patients with resected hepatocellular carcinoma
por: Chen, Ming-Yu, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_uujq5ilt2f8qim6phfgc4gfdkc